Preclinical studies of ficlatuzumab monotherapy for non-small cell lung cancer (NSCLC), which has a similar genetic profile to HNSCC [51], resulted in reduced tumor growth and decreased levels of phospho-MET, phospho-ERK, and phospho-Akt, but a concurrent increase in phospho-EGFR. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.